INSPIRE IVF Drives New S-Curve Strategy, Advancing Toward a Global Fertility and Health Innovation Platform

Inspire IVF Public Company Limited (“INSPIRE IVF”) has announced a major strategic direction to elevate its IVF business and Fertility Technology from a fertility treatment center into a comprehensive “Fertility Ecosystem Platform” that integrates medical technology, health innovation, and related businesses.

This strategy aims to create a new phase of growth for INSPIRE IVF within Thailand’s IVF and Medical Tourism industries, which continue to expand due to increasing demand for infertility treatment, family planning, and assisted reproductive technologies from both Thai and international patients.

INSPIRE IVF is focused on developing a business structure that extends beyond traditional IVF treatment by expanding into a Fertility Ecosystem that connects medical services, healthcare technology, patient care, and related businesses. This approach is designed to support the growing trends in the Fertility and Healthcare Technology markets at both regional and global levels.

This strategic move follows the company’s Annual General Meeting of Shareholders held on 23 April 2026, where shareholders unanimously approved 100% the adjustment of the IPO fundraising utilization plan and the issuance of IVF-W1 warrants to strengthen the company’s capital structure and support future investment opportunities that will become new S-Curve growth drivers.

Ms. Kesinee Kuldilok, Chief Executive Officer of Inspire IVF Public Company Limited, stated:

“This transformation represents an important milestone for Inspire IVF as we expand our role from a specialized medical service provider into a comprehensive Fertility Ecosystem that covers pre-pregnancy health care, advanced fertility treatment technologies, future health services, and digital platforms.

Inspire IVF is entering a new chapter, moving from a fertility treatment center toward becoming a Fertility Ecosystem Platform that connects technology, innovation, and healthcare services. This strategic shift is not simply business expansion, but the creation of a foundation for the company’s next phase of sustainable growth.”

To support its vision of positioning Thailand as a global hub for IVF and Medical Tourism, Inspire IVF is moving forward with investments in related businesses (Related Businesses) to strengthen treatment capabilities and enhance comprehensive patient experiences across three key areas:

1. Health & Wellness Integration

Developing healthcare services, physical recovery programs, and wellness programs for IVF patients before and after treatment, including the creation of premium health centers with international standards to support Medical Tourism customers from Thailand and overseas.

2. Advanced Genomic Technology

Investing in advanced genomic analysis technology to improve IVF treatment accuracy and enhance pregnancy success rates (IVF Success Rate) through more effective fertility solutions.

3. Digital Health Platform

Developing Digital Health and Telemedicine platforms to provide consultations, treatment monitoring, and remote medical care for patients. These platforms help reduce geographical limitations and support the expansion of IVF services to both domestic and international markets.

Capital Structure Management and IVF-W1 Warrants

Regarding capital structure management, shareholders approved the issuance of up to 137,500,000 IVF-W1 warrants to support long-term business expansion.

The warrants will be allocated to existing shareholders at a ratio of 3.2 existing ordinary shares to 1 warrant unit, with an exercise price of 0.70 baht per share and a project term of 3 years.

Warrant holders will have the right to convert the warrants into ordinary shares every 6 months.

This financial instrument was designed to increase Capital Flexibility and prepare the company for future strategic investment opportunities, including Mergers & Acquisitions (M&A) and Joint Ventures, without increasing financial burdens from borrowing.

“IVF-W1 is a financial instrument that enhances capital structure flexibility and provides existing shareholders with the opportunity to grow together with the company.

If our Fertility Ecosystem strategy expands according to plan, shareholders will benefit from this New S-Curve growth opportunity. The company remains committed to sustainable growth while maintaining careful risk management.

The platforms and capital structure we have prepared will create greater Agility, allowing us to adapt to global changes and move forward quickly when the right opportunities arise,” Ms. Kesinee added.

The unanimous 100% shareholder approval reflects strong confidence in the company’s new direction and vision for long-term growth.

Through the development of a Fertility Ecosystem Platform combined with a flexible capital structure ready to support future investments, Inspire IVF believes this transformation will mark the beginning of a new growth phase and help elevate Thailand into one of the leading centers for reproductive technology in the region.